FindTrial
Sign In

The comprehensive evaluation of therapeutic drugs for pediatric novel coronavirus pneumonia (COVID-19)

The comprehensive evaluation of therapeutic drugs for pediatric novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033342
Enrollment
Unknown
Registered
2020-05-28
Start date
2020-06-15
Completion date
Unknown
Last updated
2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:Treated with variate traditional Chinese medicines

Sponsors

Children's Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Pediatric patients diagnosed with COVID-19; (2) Treated with heat-clearing and detoxifying traditional Chinese medicines.

Exclusion criteria

Exclusion criteria: (1) Loss of efficacy and safety indices; (2) the time measuring evaluation indices does not align with the time taking medicines

Design outcomes

Primary

MeasureTime frame
Body temperature;Respiratory syndrome;Pulmonary imaging;Nucleic acid testing;—

Countries

China

Contacts

Public ContactZhiping Li

Children's Hospital of Fudan University

zplifudan@126.com+86 021-64931224

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026